UK - Welsh biopharmaceutical company receives £1m investment

The Welsh Assembly Government has invested £1m through its SMARTCymru programme to Protherics Plc, a biopharmaceutical company which has its main manufacturing operations in Ceredigion. The grant will be used to support the manufacture of Protherics’ promising anti-sepsis drug CytoFab™, which is being developed in partnership with AstraZeneca. CytoFab™ is a first in class anti-TNF-alpha polyclonal antibody fragment (Fab) product, which is being developed for the treatment of severe sepsis.